UNSPSC 51142539: Adrogolide hydrochloride

This classification denotes a dopamine agonist with the molecular formula C22H25NO4S.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 69MG3OZA0H, chemically known as benzo(f)thieno(2,3-c)quinoline-9,10-diol, 4,5,5a,6,7,11b-hexahydro-2-propyl-, diacetate (ester), hydrochloride, (5ar-trans)- but more generally known as adrogolide hydrochloride, which bears US NIH Compound Identifier 166543. Most nations, for tariff and trade purposes, schedule adrogolide hydrochloride under HS 29349990 and SITC 51579.

As of Q4 2014, ADROGOLIDE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Adrogolide hydrochloride bears US NLM identifiers UMLS ID C2347538 and NCI Concept Code C72681. SMILES: CCCC1CC2C(S1)CN[C@H]3[C@H]2C4CC(C(CC4CC3)OC(=O)C)OC(=O)C.CL.

UNSPSC 51142539 Adrogolide hydrochloride is a Commodity code that nominally describes a specific pharmaceutical active ingredient, but recent state and local opportunities tagged under this code show little alignment with that narrow scope. The three most recent solicitations on record involve naloxone procurement, direct-to-manufacturer prescription programs, and generic multi-source pharmaceuticals and OTC products—none of which reference adrogolide hydrochloride directly. The mismatch suggests either miscoding at the source or that this UNSPSC designation is being used as a catch-all for pharmaceutical-supply acquisitions more broadly. Issuing bodies include county health departments (Seminole County, Florida), state HHS commissions (Texas), and regional cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance serving multiple states including Oregon). The work ranges from direct product procurement of specific units to market-intelligence gathering on alternative supply models.

Recent activity centers on Florida and Minnesota, with a secondary signal from Texas HHS. The Seminole County solicitation (IFB60459723LAS, due July 26, 2026) seeks 1,900 units of naloxone and 800 safe drug deactivation systems annually through competitive bidding with quarterly deliveries to a county health facility. The Minnesota MMCAP RFP (S1070000015802, due March 26, 2026) established multiple-award contracts for generic pharmaceuticals and OTC products through three authorized wholesalers, with evaluation weighted 75 percent on price competitiveness and 25 percent on administrative and technical factors including cGMP and DSCSA compliance. The Texas HHS Commission's RFI (HHS0017013, April 3, 2026) represented early-stage market research on direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager channels, designed to inform future formal RFP strategy rather than bind immediate procurement. None of the three opportunities specify explicit set-aside designations for disadvantaged enterprises, though all impose federal compliance requirements and standard insurance and eligibility verification mandates.